Irisin in PCOS and its change with metformin therapy.
Not Applicable
Completed
- Conditions
- Health Condition 1: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2023/03/050982
- Lead Sponsor
- TELAGAREDDY RADHA KRISHNA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 77
Inclusion Criteria
1.Confirmed cases of PCOS
2. Age 18â??40 years
3. All PCOS women who did not receive oral contraceptives,
insulin-sensitizing agents, antiandrogens, or glucocorticoids in the past 3 months.
4. Age and sex matched healthy adults are included in control group
Exclusion Criteria
1. Other causes for hyperandrogenemia and ovulatory dysfunction including
a. 21-alpha hydroxylase deficiency,
b. Congenital adrenal hyperplasia, and
c. Cushingâ??s syndrome
2. T1DM
3. T2DM
4. Smokers.
5. Alcoholics.
6. Medicines that affect glucose/lipids/androgen metabolism within past 3 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EVELS OF IRSIN IN PCOS <br/ ><br>CHANGE IN IRISIN WITH METFORMINTimepoint: 6 MONTHS
- Secondary Outcome Measures
Name Time Method CHANGE IN IRISIN WITH METFORMINTimepoint: 6 months